Zymeworks Inc. Common Stock (ZYME) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.41 Million) by net assets ($320.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ZYME market cap for the company's overall valuation and market capitalisation.
Zymeworks Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zymeworks Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zymeworks Inc. Common Stock ranked by their cash flow conversion efficiency. Explore how high is Zymeworks Inc. Common Stock's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyosung Corp
KO:004800
|
0.117x |
|
Austevoll Seafood ASA
OL:AUSS
|
0.066x |
|
OVH Groupe SAS
PA:OVH
|
10.219x |
|
Dime Community Bancshares, Inc.
NYSE:DCOM
|
0.037x |
|
Fidelis Insurance Holdings Limited
NYSE:FIHL
|
0.102x |
|
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
|
0.024x |
|
Xinhuanet Co Ltd
SHG:603888
|
0.034x |
|
Grupo Bafar S.A.B. de C.V
MX:BAFARB
|
0.056x |
Annual Cash Flow Conversion Efficiency for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Zymeworks Inc. Common Stock from 2014 to 2024. View Zymeworks Inc. Common Stock stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $338.77 Million | $-110.04 Million | -0.325x | -27.63% |
| 2023-12-31 | $464.81 Million | $-118.30 Million | -0.255x | -187.06% |
| 2022-12-31 | $492.96 Million | $144.11 Million | 0.292x | +137.84% |
| 2021-12-31 | $249.09 Million | $-192.45 Million | -0.773x | -109.18% |
| 2020-12-31 | $409.92 Million | $-151.40 Million | -0.369x | -10.86% |
| 2019-12-31 | $245.68 Million | $-81.85 Million | -0.333x | -348.72% |
| 2018-12-31 | $180.49 Million | $24.18 Million | 0.134x | +7021.35% |
| 2017-12-31 | $116.43 Million | $219.00K | 0.002x | +100.05% |
| 2016-12-31 | $9.00 Million | $-35.25 Million | -3.915x | -222.11% |
| 2015-12-31 | $18.24 Million | $-22.17 Million | -1.216x | -589.12% |
| 2014-12-31 | $39.78 Million | $-7.02 Million | -0.176x | -- |
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more